Overview
The safety question splits into three, and they have quite different answers.
What happens during the session is the most predictable part, and it is manageable.
Who should not have it is a short and specific list.
Where the preparation comes from and who is supervising is the part that varies most between providers, and it is where the real differences in risk sit.
| What to know | |
|---|---|
| During the infusion | Flushing, nausea, chest tightness, cramping — rate-dependent. Settle when slowed |
| After the session | Generally uneventful. Local soreness with intramuscular administration |
| Regulatory status | Compounded. Not FDA-approved — see below |
| Sterility and sourcing | The substantive risk. Depends entirely on the pharmacy and the setting |
| Long-term safety data | Not established |
| Should not have it | Pregnancy, breastfeeding, active or prior cancer without oncology input, significant kidney or liver impairment |
The single most useful thing to know before a first session: the unpleasant effects are almost entirely about rate. Given slowly, most people are comfortable. Given quickly, most people are not. If you feel them, say so — the correct response is to slow the infusion, not to push through.
What happens during a session
These are common, well described and not dangerous in a supervised setting.
Flushing, warmth and a feeling of pressure in the chest. Nausea, sometimes significant. Abdominal cramping. Headache. A general sense of unease that people describe in varied ways.
All of these are rate-dependent. They appear when the infusion runs fast and settle within minutes when the rate is reduced. This is why infusions take the time they do, and why a faster session is not a shortcut — it is the same delivery with more discomfort.
Anyone administering this should be monitoring you and adjusting. If that is not happening, that is a reason to ask questions rather than to endure it.
Intramuscular injection is a different experience — shorter, with less of the rate-related sensation, and with the usual soreness where it is given.
Where the real risk sits
This is the part that gets the least attention and deserves the most.
Injectable and infusible NAD+ is compounded, not FDA-approved. It has not been evaluated by the FDA for safety, effectiveness or batch-to-batch consistency. The full regulatory picture.
Which means the safety of what goes into you depends on where it was made and under what standards. There is a meaningful difference between a state-licensed compounding pharmacy and an FDA-registered outsourcing facility, which operates under stricter manufacturing requirements.
Anything administered intravenously carries infection risk if sterility is not maintained — that is true of any infusion and it is not specific to NAD+. It is why the setting matters: a supervised clinical environment with trained staff and a known supply chain is a different proposition from an informal one.
Reasonable questions to ask any provider: where is this compounded, is the pharmacy a 503A or a 503B facility, who is administering it, what monitoring happens during the session, and what happens if I react.
A provider who cannot answer those readily is telling you something.
The regulatory position on NAD+ in compounding has been under FDA review and has developed over time. Anyone offering this should be tracking it.
Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product.
Who should not have it
Pregnancy and breastfeeding. Safety has not been established.
Active cancer, or a history of it, without oncology input. NAD+ is involved in cellular metabolism and DNA repair — processes relevant to cancer biology in ways that are not fully characterized. This is not a claim of harm; it is an area where the biology is genuinely unresolved, and the appropriate step is a conversation with your oncology team rather than a decision made independently.
Significant kidney or liver impairment, which affects how anything administered is handled.
Anyone who has reacted badly to a previous infusion.
Anyone on a complex medication regimen, without that being reviewed first. What to disclose.
And more generally: if you are under specialist care for anything significant, that clinician should know what you are having. Treatments obtained outside a primary care relationship frequently do not make it onto the record.
What is not established
Stated plainly, because it belongs in a safety discussion.
Long-term safety data does not exist. There are no studies following people receiving repeated NAD+ infusions over years.
Interaction data is limited. More on that.
There is no monitoring test. NAD+ levels are not measured in routine clinical practice, there is no established threshold, and no blood test tells you whether a course is doing anything or whether you have had too much.
None of that means harm has been demonstrated. It means the reassurance available is based on the absence of reported problems in a setting without systematic data collection, which is weaker than the reassurance that comes from long-term studies.
What makes a session safer
A clinical setting with trained staff who can recognize and respond to a reaction.
A slow rate, adjusted to how you are doing rather than to the schedule.
A known compounding source, ideally an FDA-registered outsourcing facility.
A conversation beforehand covering your medications, your medical history and anything you are under specialist care for.
Someone paying attention during the session, not just afterwards.
Frequently asked questions
Is a NAD+ injection safe? The common effects during a session — flushing, nausea, chest tightness, cramping — are rate-dependent and settle when the infusion is slowed. The more substantive considerations are the compounded regulatory status, sterility and sourcing, and who should avoid it.
What does it feel like? If given too quickly, uncomfortable — flushing, nausea and chest tightness are common. Given slowly, most people are fine. Tell whoever is administering it if you feel these.
Is it FDA-approved? No. It is compounded, which means it has not been reviewed for safety, effectiveness or batch consistency.
Who should not have it? Anyone pregnant or breastfeeding, anyone with active cancer or a cancer history without oncology input, anyone with significant kidney or liver impairment, and anyone who has reacted to a previous infusion.
Can I have too much? There is no established monitoring test or threshold, which is part of why supervision and a sensible course structure matter.
Where this fits in your plan
The useful version of this question is not "is it safe" in the abstract but "is this preparation, in this setting, appropriate for me" — and that has answers.
Ask where it is compounded, who is supervising, and what happens if you react. And make sure whoever manages your care knows you are having it. What NAD+ therapy involves here, and what we check first.
We measure first. Then we act.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
